文献速递眼底病与葡萄膜炎

玻璃体腔注射阿柏西普与增殖性糖尿病视网膜病变患者OCTA血管密度变化的关联

Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该研究为RECOVERY随机临床试验的二次分析,纳入40眼增殖性糖尿病视网膜病变无黄斑水肿患者,随机接受每月或每季度2mg阿柏西普注射治疗12个月。

要点

  • 增殖性糖尿病视网膜病变无黄斑水肿患者接受阿柏西普治疗12个月,黄斑血管密度无显著变化
  • 每月与每季度注射组间血管密度参数无差异

核心结论

  • 玻璃体腔注射阿柏西普治疗12个月后,黄斑血管密度未发生显著变化。
  • 鉴于糖尿病视网膜病变中非灌注预期会进展,该发现可能代表抗VEGF治疗与黄斑血管密度之间存在有益关联。

研究设计与样本

  • RECOVERY随机临床试验的二次分析(post hoc分析),纳入40例增殖性糖尿病视网膜病变无糖尿病黄斑水肿患者的40只眼。
  • 患者随机分入每月(n=20)或每季度(n=20)接受2mg阿柏西普注射组,治疗12个月。
  • 12个月时3例失访,5例因OCTA图像质量差被排除,最终每组各16例(共32眼)纳入分析。
  • OCTA分析样本平均年龄48.37岁(SD 12.30),男性17例(53.1%)。

主要发现

  • 12个月时每月注射组与每季度注射组之间血管密度参数无差异。

临床怎么用

  • 对于增殖性糖尿病视网膜病变无黄斑水肿患者,抗VEGF治疗12个月未导致OCTA测得的黄斑血管密度显著下降。
  • 该结果提示抗VEGF治疗可能不会加剧本已存在的视网膜非灌注,但需结合临床综合判断。

局限性

  • 本研究为二次分析,最终分析样本量较小(每组16例)。
  • 5例因OCTA图像质量差被排除,可能引入选择偏倚。
  • 随访时间仅12个月,缺乏更长期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although previous studies have evaluated the association between anti-vascular endothelial growth factor therapy and macular vessel density, they were confounded by the presence of macular edema, which may be associated with artifacts and segmentation errors in optical coherence tomography angiography (OCTA). OBJECTIVE: To evaluate the association of intravitreal aflibercept with changes in macular vascular density using OCTA in patients with proliferative diabetic retinopathy without diabetic macular edema. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial used data on 40 eyes of 40 patients with proliferative diabetic retinopathy without diabetic macular edema who were enrolled in the Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy (RECOVERY) clinical trial from August 1, 2016, to June 31, 2017. Three patients were lost to follow-up at month 12, and 5 patients were excluded from analysis because of poor OCTA image quality, leaving 16 patients in each cohort in the final analysis. Data analysis was performed from March 1, 2018, to January 15, 2019. INTERVENTION: In the RECOVERY trial, patients were randomized into cohorts receiving 2 mg of aflibercept injections monthly (n = 20) or quarterly (n = 20) and treated for 12 months. MAIN OUTCOMES AND MEASURES: The percentage of vascular density (in total scan and foveal and parafoveal regions) was compared before and after 12 months of therapy. RESULTS: The sample for this OCTA analysis included 32 eyes from 32 patients (mean [SD] age, 48.37 [12.30] years; 17 [53.1%] male). The mean (SD) total scan vascular density for the superficial vascular complex was 42.28% (4.03%; 95% CI, 40.63%-43.93%) at baseline and 39.64% (4.01%; 95% CI, 37.91%-41.37%) at month 12 (P = .69). For the deep vascular complex, the mean (SD) vascular density was 48.42% (4.99%; 95% CI, 46.36%-50.47%) at baseline and 45.69% (4.63%; 95% CI, 43.69%-47.70%) at month 12 (P = .40). For the choriocapillaris, the mean (SD) vascular density was 64.42% (3.36%; 95% CI, 63.04%-65.81%) at baseline and 62.55% (4.79%; 95% CI, 60.48%-64.62%) at month 12 (P = .16). There was no difference in vascular density parameters between monthly and quarterly injection arms at month 12. CONCLUSIONS AND RELEVANCE: In this study, macular vascular density did not change after 12 months of intravitreal aflibercept therapy. Because nonperfusion is expected to progress in diabetic retinopathy, this finding may represent a beneficial association between anti-vascular endothelial growth factor therapy and macular vascular density. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02863354.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Alagorie AR, Nittala MG, Velaga S, et al. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32584384. doi:10.1001/jamaophthalmol.2020.2130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。